2022 Impact Factor
2.3

EDITORS IN CHIEF
M. B. Bilò (Italy)
P. Carreiro-Martins (Portugal)

DEPUTY EDITORS

R. Rodrigues Alves (Portugal)
D. Villalta (Italy)

ASSOCIATE EDITORS

R. Asero (Italy)
M. Branco Ferreira (Portugal)

L. Cecchi (Italy)
E. Scala (Italy)
D. Solé (Brasil)
G. Sturm (Austria)

EDITORIAL BOARD
I. Agache (Romania)
I. Annesi Maesano (France)
L. Antonicelli (Italy)
G. Azizi (Iran)
L.M. Borrego (Portugal)
K. Brockow (Germany)
S. Bavbek (Turkey)
E. Cichocka-Jarosz (Poland)
M. Cugno (Italy)
L. Delgado (Portugal)
P. Demoly (France)
G. D'Amato (Italy)
S. Durham (UK)
M. Faber (Belgium)
M. Fernandez-Rivas (Spain)
J. Fonseca (Portugal)
ZS. Gao (China)
G.P. Girolomoni (Italy)
E. Goudouris (Brasil)
A. Grumach (Brasil)
G. Kostantinou (Greece)
F. Levi-Shaffer (Israel)
M. Maurer (Germany)
L. Mayorga (Spain)
C. Micheletto (Italy)
M. Morais de Almeida (Portugal)
G. Moscato (Italy)
A. Musarra (Italy)
C. Nunes (Portugal)
M. Ollert (Lussemburgo)
P. Parronchi (Italy)
G. Passalacqua (Italy)
E. Pedro (Portugal)
A. Perino (Italy)
O. Quercia (Italy)
A. Romano (Italy)
G. Scadding (UK)
A. Todo Bom (Portugal)
A. Tedeschi (Italy)
R. van Ree (Netherland)
S. Voltolini (Italy)

FOUNDERS

F. Bonifazi (Italy)
A. Sabbah (France)

*************************

Chief Executive Officer
Ludovico Baldessin

Editorial Coordinator
Barbara Moret

Publishing Editor
Jessica Guenzi
j.guenzi@lswr.it

Sales

dircom@lswr.it

EDRA SpA
Via G. Spadolini, 7

20141 Milano - Italy
Ph. 0039 (0)2-88184.1
Fax 0039 (0)2-88184.301
www.edraspa.it

Follow us on LinkedIn

Table of Contents »

Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab

M. Noshela Ghazanfar¹ misbah.noshela.ghazanfar@regionh.dk, S.F. Thomsen^1,2

Show more: Authors information and Publication history

Doi
https://doi.org/10.23822/EurAnnACI.1764-1489.08

Summary
Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.

FULL TEXT

Cite this article as:
Ghazanfar MN, Thomsen SF. Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab. Eur Ann Allergy Clin Immunol. 2017;49(6):284-285. doi:10.23822/EurAnnACI.1764-1489.08